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Abstract: Direct oral anti-activated factor X and antithrombin agents have largely replaced vitamin
K antagonists as the standard of care in treatment of venous thromboembolism. However, gaps in
efficacy and safety persist, notably in end-stage renal disease, implantable heart valves or assist devices,
extracorporeal support of the circulation, and antiphospholipid syndrome. Inhibition of coagulation
factor XI (FXI) emerges as a promising new therapeutic target. Antisense oligonucleotides offer potential
advantages as a prophylactic or therapeutic modality, with one dose-finding trial in orthopedic surgery
already published. In addition, monoclonal antibodies blocking activation and/or activity of activated
factor XI are investigated, as are small-molecule inhibitors with rapid offset of action. Further potential
targets include upstream components of the contact pathway such as factor XII, polyphosphates, or
kallikrein. Finally, catheter-directed, pharmacomechanical antithrombotic strategies have been developed
for high- and intermediate-risk pulmonary embolism, and large randomized trials aiming to validate their
efficacy, safety, and prognostic impact are about to start.
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directed,	 pharmacomechanical	 antithrombotic	 strategies	 have	 been	 developed	 for	
high-	and	intermediate-	risk	pulmonary	embolism,	and	large	randomized	trials	aiming	
to	validate	their	efficacy,	safety,	and	prognostic	impact	are	about	to	start.
K E Y W O R D S
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Essentials
• Direct oral anticoagulants have been used as a standard of care in venous thromboembolism.
• There are gaps in their efficacy and safety in specific patient subgroups.
• Inhibition of coagulation factor XI seems to be a promising new therapeutic target.
•	 Factor	XII,	polyphosphates,	kallikrein	inhibition,	and	catheter-	directed	strategies	are	also	emerging.
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1  |  INTRODUC TION: VENOUS 
THROMBOEMBOLISM A S A GROWING 
CHALLENGE FOR SOCIETIES
Venous	thromboembolism	(VTE),	clinically	presenting	as	deep	vein	
thrombosis	 (DVT)	 or	 acute	 pulmonary	 embolism	 (PE),	 is	 the	 third	
most frequent acute cardiovascular syndrome after myocardial 
infarction	and	stroke.1	The	 incidence	of	VTE	 is	almost	eight	 times	
higher	in	individuals	aged	≥80	years	than	in	the	fifth	decade	of	life,2 
and	 thus,	 as	 societies	 age	worldwide,	 annual	 VTE	 incidence	 rates	
continue to increase over time.3,4	Recently,	an	analysis	of	vital	regis-
tration	data	from	the	World	Health	Organization	(WHO)	Mortality	
Database	 investigated	the	trends	 in	annual	PE-	related	mortality	 in	





the elderly in many countries.5	A	further	study	analyzing	the	trends	
in	North	America	revealed,	for	the	first	time,	a	“rebound”	increase	
in	PE-	related	mortality	among	young	and	middle-	aged	adults	in	the	
United	States	since	2006.6 These facts illustrate the magnitude of 
the	burden	and	multitude	of	challenges	that,	 in	spite	of	the	recent	
advances	 in	the	prevention	and	treatment	of	 thrombosis,	VTE	will	
continue to impose on populations and health care systems world-
wide in the years to come.
This article reviews the current standard of care following a de-
cade	of	revolution	in	anticoagulation,	and	outlines	the	most	prom-
ising	 fields	of	ongoing	research	and	the	populations	most	 likely	 to	
benefit from emerging antithrombotic agents and strategies in the 
decade to come.
2  |  ANTICOAGUL ATION AND 
ANTITHROMBOTIC STR ATEGY FOR V TE: 
THE PA ST AND THE CURRENT STATE OF 
THE ART
For	many	decades	and	until	very	recently,7,8 the standard approach 
to initiating anticoagulation treatment in a patient with acute 
VTE	 consisted	 of	 parenteral	 (subcutaneous)	 weight-	adjusted	 low-	
molecular-	weight	 heparin	 (LMWH)9	 or	 fondaparinux10 administra-
tion;	 (intravenous)	 unfractionated	 heparin	 (UFH)	 infusion	 is	 now	
mainly reserved for patients presenting with hemodynamic compro-
mise or severely reduced renal function.11 In parallel with parenteral 













window	 and	 exhibit	 substantial	 variations	 in	 bioavailability	 and	 in	
interpatient	 as	 well	 as	 intrapatient	 dose	 requirement,13 and need 
routine	laboratory	monitoring.	These	challenges,	along	with	a	multi-
tude	of	drug-	drug	interactions	and,	in	association	with	all	the	above,	
a	 persistently	 elevated	 risk	 for	 major,	 potentially	 life-	threatening	
bleeding	during	chronic	administration,14,15 have limited the use of 
these	 drugs	 and	 thus	 the	 implementation	 of	 long-	term	 secondary	
prevention	after	an	index	episode	of	VTE	in	clinical	practice.16 The 
direct	 oral	 anticoagulants	 (DOACs)	were	 developed	 and	 approved	
in	 the	 past	 decade	 with	 the	 aim	 to	 overcome	 these	 weaknesses	
and	deficits.	DOACs	are	small	molecules	 that,	 in	contrast	 to	UFH,	
LMWH,	 fondaparinux,	 and	 the	VKAs,	 inhibit	directly a single acti-
vated	coagulation	factor;	the	target	is	thrombin	for	dabigatran,	and	
activated	 factor	X	 (FXa)	 for	 apixaban,	 edoxaban,	 rivaroxaban,	 and	







safety	 results	 of	 these	 trials,	 in	 Table	 1.	Meta-	analyses	 have	 con-
firmed	 the	noninferiority	of	DOACs	compared	 to	 the	combination	
of	LMWH	with	a	VKA	for	prevention	of	symptomatic	or	lethal	VTE	
recurrence,	 along	 with	 significantly	 reduced	 rates	 of	 major,	 life-	
threatening bleeding18;	 these	 safety	 data	 are	 supported	 by	 “real-	
world”	 evidence.15,19	 In	 addition,	 DOACs	 have	 been	 successfully	
tested	as	part	of	a	single-	oral-	drug	anticoagulation	strategy,	which	
helps	to	avoid,	in	eligible,	hemodynamically	stable	patients,	the	need	









in the general population and in selected patients with cancer.11,25–	28
3  |  UNANSWERED QUESTIONS AND 
REMAINING GAPS IN THE DOAC ER A
Based	on	the	efficacy	and	particularly	 the	very	good	safety	pro-
file	 of	 the	 DOACs,	 as	 demonstrated	 by	 the	 large	 trials	 summa-
rized	 in	 Table	 1,	 current	 guidelines11,25 recommend to consider 
an	 extended	 secondary	 prevention	 of	 indefinite	 duration	 in	 the	
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majority	of	patients	after	 a	 first	 episode	of	VTE.	Apart	 from	pa-
tients	who	have	suffered	multiple	episodes	of	VTE,	potential	can-
didates	 include	also	 those	with	no	 identifiable	 risk	 factor	 for	 the	
index	event	(so-	called	unprovoked	VTE),	patients	with	a	persistent	
risk	 factor	 including	 cancer,	 and	 those	with	 a	 weak	 transient	 or	






than	 in	 the	 VKA	 era,	 life-	threatening	 bleeding	 complications	 do	
occur	 among	 patients	 taking	DOACs	 in	 everyday	 practice,15,19,32 
and we may witness an increase in their absolute numbers in the 
future,	notably	among	patients	with	VTE	who	now	receive	lifelong	
secondary	prophylaxis	 instead	of	 the	3-	month	or	6-	month	 treat-
ment periods in the past.
This	 risk	 of	 bleeding	 in	 an	 aging	 population	 with	 thrombotic	
events	may	 be	 related,	 among	 others,	 to	 a	 progressive	 decline	 in	
renal	 function.	 This	 caveat	 particularly	 applies	 to	DOACs	 as	 small	
molecules	that	undergo,	to	a	varying	but	in	all	cases	significant	ex-








the	 trials	 investigating	 rivaroxaban,	edoxaban,	 and	dabigatran,	 the	
lowest	acceptable	eGFR	was	30	mL/min.11,17	At	the	far	end	of	the	
severity	spectrum,	patients	with	end-	stage	renal	disease	on	hemo-
dialysis are a particularly vulnerable group with a high thrombotic 
risk	but	at	 the	same	time	also	a	high	bleeding	risk	on	anticoagula-
tion.33	 Notwithstanding	 some	 encouraging	 preliminary	 data,34–	36 
the	DOACs	 have	 not	 been	 able	 to	 convincingly	 show	 a	 favorable	
risk-	to-	benefit	clinical	profile	in	this	growing	population.
Clinical trials37	as	well	as	ex	vivo	studies38 conducted soon after 
DOAC	 approval,	 indicated	 that	 these	 drugs,	 by	 targeting	 a	 single	
specific coagulation factor downstream of the contact pathway 
(which	 is	 shown	on	 the	 left	 side	of	Figure	1),	may	possess	neither	






Finally,	 concerns	 have	 been	 raised	 on	 the	 efficacy	 and	 safety	
of	DOACs	 in	 patients	with	 the	 antiphospholipid	 syndrome;	 this	 is	
diagnosed when arterial or venous thrombotic events are accom-
panied	 by	 laboratory	 abnormalities,	 notably	 any	 combination	 of	
positive lupus anticoagulant and elevated titers of anticardiolipin or 
β2-	glycoprotein	I	antibodies.39	Based	on	the	available	clinical	data,40 
scientific	 societies	 currently	 recommend	 that	 patients	with	 triple-	
positive	 laboratory	 findings,	 or	 those	 with	 the	 antiphospholipid	
syndrome	who	have	suffered	arterial	thromboembolism,	be	treated	
with	a	VKA	instead	of	a	DOAC.11,41 Previously considered a rather 
marginal	topic,	 the	prognostic	 impact	and	therapeutic	 implications	
of antiphospholipid antibodies suddenly moved into the center of in-
terest	in	the	year	2020,	following	reports	on	the	frequent	detection	
and possible thrombogenicity of such antibodies in patients hospi-
talized	with	coronavirus	disease	2019	(COVID-	19).42–	44
4  |  NE W ANTICOAGUL ANTS TARGETING 




the	 antithrombin-	mediated	 effects	 of	 heparin,	 LMWH,	 or	 fonda-
parinux)	one	of	the	two	key	proteases	of	the	common	pathway,	FXa	
or	thrombin,	the	DOACs	have	been	shown	to	possess	high	antico-
agulant efficacy. They also demonstrated a safer profile compared 
to	VKAs,	mostly	thanks	to	their	(more)	predictable	pharmacokinet-
ics	 and	 stable	 anticoagulant	 effect.	 Nevertheless,	 bleeding	 does	
remain	a	concern	with	these	drugs,45	a	fact	that	is	to	be	expected	
in light of the central role of their target proteins for hemostasis. 
Consequently,	attention	has	turned	to	upstream	components	of	the	
so-	called	contact	system	as	possibly	even	safer	targets,	at	least	for	
particular patient groups and in particular clinical situations as out-
lined	above.	Most	of	the	existing	epidemiological	and	experimental	
data	point	to	factor	XI	(FXI),46 which is activated by activated fac-
tor	XII	(FXIIa)	and	maximizes	thrombin	generation	via	the	intrinsic	
tenase	 complex	 activated	 factor	 IX–	activated	 factor	VIII	without	
interfering	with	the	interaction	between	factor	VII	and	tissue	fac-
tor	(Figure	1).	The	properties	and	main	fields	of	investigation	for	in-






tion,	 including	polypeptides;	 peptidomimetic	 active	 site	 inhibitors;	
polymeric	glycosaminoglycans	 (GAGs)	and	 their	 saccharide	mimet-
ics;	 nonpolymeric,	 nonsaccharide	GAG	mimetics;	 antibodies;	 anti-
sense	oligonucleotides	 (ASOs);	and	aptamers.47 Of those currently 
under	advanced	clinical	investigation,	ASOs,	which	are	short	nucle-
otide	 sequences	 complementary	 to	 specific	 mRNA	 targets,	 offer	
a number of potential advantages as prophylactic or therapeutic 
modalities (reviewed in Zhang et al.48):	 (i)	The	liver,	 in	which	FXI	 is	
primarily	synthesized,	 is	one	of	the	most	sensitive	tissues	for	ASO	
therapy;	 (ii)	 second-	generation	 ASOs	 exhibit	 dose-	linear	 and	 pre-
dictable	 pharmacokinetics	 in	 humans;	 (iii)	 ASOs	 have	 prolonged	
tissue	 elimination	 half-	lives	 and	 thus	 do	 not	 need	 frequent	 ad-
ministration,	 facilitating	patient	compliance;	 (iv)	ASOs	offer	a	high	
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TA B L E  1 Phase	3	randomized	controlled	trials,	which	led	to	the	approval	of	DOACs	for	treatment	and	(extended)	secondary	prevention	
of	VTE










150 mg twice daily versus parenteral 
anticoagulant/warfarin
6	months 2589 Recurrent	or	fatal	VTE:	D:	2.3%	compared	to	 Major	bleeding:	D:	1.2%	compared	to	
Extension trials




RE-	MEDY29 Double-	blind;	noninferiority Dabigatran 150 mg twice daily versus warfarin 6-	36	months 2856 Recurrent	or	fatal	VTE:	D:	1.8%	compared	to	 Major	or	CRNM	bleeding:	D:	5.6%	
Rivaroxaban EINSTEIN-	DVT22 Open-	label;	noninferiority Rivaroxaban	(15	mg	twice	daily	for	3	weeks,	then	
20	mg	once	daily)	versus	enoxaparin/warfarin









EINSTEIN	Extension22 Double-	blind;	superiority Rivaroxaban	20	mg	once	daily	versus	placebo 6-	12	months 1196 Recurrent	VTE:	R:	1.3%	compared	to	placebo:	 Major	bleeding:	R:	0.7%	compared	to	
EINSTEIN	Choice23 Double-	blind;	superiority Rivaroxaban	20	mg	once	daily	or	rivaroxaban	






























efficacy	 and	 safety	 in	 primates,49,50	 the	 FXI	ASO	 Ionis-	416858	or	
Ionis-	FXI	Rx	(also	known	as	BAY-	2306001)	is	already	at	an	advanced	
stage	of	clinical	 testing	 (Table	2),	with	one	dose-	finding	trial	 in	or-
thopedic surgery already published51	 (Table	 3).	 Another	 FXI	 ASO,	
















2 trial in orthopedic surgery53	 (Table	 3).	 Another	 antibody,	 abel-





dent on hepatic and renal function for their metabolism and clear-
ance;	on	the	other	hand,	 they	offer	 the	advantage	of	 rapid	onset	
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 Phase	3	randomized	controlled	trials,	which	led	to	the	approval	of	DOACs	for	treatment	and	(extended)	secondary	prevention	
of	VTE
Treatment duration Patients randomized Efficacy outcome: VTE recurrence Safety outcome: Bleeding












RE-	MEDY Double-	blind;	noninferiority 6-	36	months 2856 Recurrent	or	fatal	VTE:	D:	1.8%	compared	to	
warfarin: 1.3%
Major	or	CRNM	bleeding:	D:	5.6%	
compared to warfarin: 10.2%






























0.2% compared to placebo: 0.5%



















aspirin and clopidogrel for 21 days followed by aspirin thereaf-
ter	 (NCT03766581).	 Another	 oral	 small-	molecule	 inhibitor,	 BAY-	
2433334,	 is	 being	 investigated	 against	 apixaban	 in	 patients	with	





be well suited for use in a critical care environment and particularly 
for	patients	on	extracorporeal	membrane	oxygenation.55
5  |  AGENTS TARGETING OTHER 
COAGUL ATION FAC TORS
Although	FXI	 is	 formally	 considered	 a	 component	of	 the	 contact	
pathway	and	 lies	upstream	of	FX	and	thrombin,	 it	 is	activated	by	
thrombin,	having	been	formed	via	the	extrinsic	pathway	(following	
activation	of	 factor	VII	 [FVIIa]	by	 tissue	factor),	and	plays	 in	 turn	
an	 important	 role	 on	 amplifying	 thrombin	 generation	 (Figure	 1).	
Consequently,	 FXI	 does	 play	 a	 relevant	 role	 in	 the	 physiology	 of	
hemostasis,	and	 it	 is	not	surprising	that	 its	 inhibition	by	the	most	
effective dose of the monoclonal antibody osocimab in a phase 2 
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epidemiological	 evidence	 (reviewed	 in	Fredenburgh	et	 al.46)	 does	
not	support	a	role	for	FXII	in	thrombosis	in	humans	and	other	pri-
mates	 as	 opposed	 to	 small	mammal	 (rodent)	models.	 At	 present,	
FXII	 inhibition	 is	 being	 investigated	 for	 hereditary	 angioedema,	
which	is	not	a	prothrombotic	condition.	Specifically,	CSL-	312	(ga-
radacimab),	a	fully	humanized	IgG4	monoclonal	antibody	targeting	
FXIIa,	 is	being	 tested	 in	 a	phase	2	 trial	 for	 subcutaneous	and	 in-
travenous	use	 (NCT03712228)	 in	 that	condition.	The	same	agent	
is also undergoing investigation in a phase 2 clinical study for 







small	 molecules,	 may	 be	worth	 pursuing	 as	 antithrombotic	 agents,	
also having a favorable safety profile.58–	60	In	addition,	recent	studies	
on	the	structure	of	plasma	kallikrein,61,62 and on its contribution to 
FIX	activation	and	thrombin	generation	independently	from	FXIa63,64 
have	redrawn	attention	to	this	long	“forgotten”	protein	of	the	contact	
pathway.65	 In	 the	 future,	kallikrein	 inhibitors,	currently	under	study	
for	 hereditary	 angioedema,66	 might	 extend	 our	 armamentarium	 of	
antithrombotic agents. Clinical evaluation of other proteases of the 
contact	pathway	downstream	of	FXI,	namely,	FVIII	or	FIX,	is	not	being	
pursued	at	present.	A	number	of	antibodies,	RNA	aptamers,	and	small	
molecules	 were	 developed	 to	 inhibit	 these	 factors	 (summarized	 in	
Mackman	et	al.67),	but	clinical	testing	was	terminated	due	to	lack	of	
efficacy or because of safety concerns.
Aspirin	 may	 have	 antithrombotic	 properties	 beyond	 classical	
inhibition	 of	 platelet	 aggregation,68	 and	 it	 was	 reported	 to	 exert	
moderate	protective	effects	against	VTE	recurrence.69,70	However,	
aspirin is inferior to standard anticoagulant treatment for secondary 
VTE	prevention,23 and its use may thus be considered only in the 
rare	case	of	a	patient	who	refuses	to	take	or	is	unable	to	tolerate	any	
form or oral anticoagulation.11
Dose-	dependent	 tissue	 factor	 inhibition71	 may	 contribute,	
along with thrombomodulin activation72	 and	 stimulation	 of	 anti-	
inflammatory	 mechanisms,73 to the antithrombotic effects of 
statins,	 and	 the	 impact	 of	 these	 drugs	 on	 the	 coagulation	 system	
may	be	 independent,	 at	 least	 in	 part,	 from	 their	 lipid-	lowering	 ef-
fects.74	 Although	 the	 use	 of	 statins	 has	 been	 associated	 with	 a	
lower	 incidence	 of	 first	 and	 recurrent	VTE,75,76 direct comparison 
with	 “standard-	of-	care”	 antithrombotic	 drugs	 is	 needed	 before	
statins	can	be	recommended	for	primary	or	secondary	VTE	preven-
tion	in	clinical	practice.	The	phase	3	investigator-	initiated	placebo-	
controlled	 Statins	 for	 Venous	 Event	 Reduction	 in	 Patients	 With	
Venous	Thromboembolism	(SAVER;	NCT04319627)	trial	is	currently	
investigating this aspect.
6  |  ANTHITHROMBOTIC STR ATEGIES 
BE YOND ANTICOAGUL ATION: FOCUS ON 
PERCUTANEOUS C ATHETER- DIREC TED 
TECHNIQUES
Beyond	 anticoagulation,	 which	 is	 the	 standard	 of	 care	 for	 all	 pa-
tients	 with	 VTE	 regardless	 of	 clinical	 presentation	 and	 severity,	
F I G U R E  1 Simplified	overview	of	the	coagulation	cascade,	highlighting	the	targets	of	currently	investigated	new	anticoagulants.	a,	
activated	(coagulation	factor);	F,	(coagulation)	factor;	NETs,	neutrophil	extracellular	traps;	poly-	P,	polyphosphates;	thrombin,	factor	IIa
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reperfusion	 treatment	 using	 standard-	dose	 fibrinolysis	 is	 recom-
mended	as	a	life-	saving	option	for	acute	PE	associated	with	hemo-
dynamic	 instability	 and	 a	 high	 risk	 of	 early	 death.11 On the other 
hand,	 in	 apparently	 stable patients presenting with laboratory 
and	 imaging	 signs	 of	 right	 ventricular	 dysfunction	 (so-	called	
intermediate-	risk	PE),	standard-	dose	intravenous	fibrinolysis,	given	
on	 top	 of	 heparin	 anticoagulation,	 provided	 no	 net	 clinical	 ben-
efit	 in	 the	 Pulmonary	 Embolism	Thrombolysis	 (PEITHO)	 trial.77 In 
that	 study,	 the	 increased	 incidence	of	 life-	threatening	bleeding	 in	
the	fibrinolysis	group	exceeded	the	achieved	reduction	 in	the	risk	
of early hemodynamic decompensation and death.77	 At	 present,	
the question whether an appropriately selected group of patients 
with	intermediate-	high-	risk	PE	may	benefit	from	early	reperfusion,	
remains to be answered.78	Over	the	past	years,	efforts	have	been	
made	to	better	identify	such	a	higher-	risk	group	based	on	a	combi-
nation	of	clinical,	laboratory,	and	imaging	criteria,79	and	to	explore	
safer reperfusion options.80 Of the reperfusion strategies currently 
available	 (visually	summarized	 in	Figure	2),	 reduced-	dose	systemic	
fibrinolysis	 and	 catheter-	directed	 thrombus	 suction	 or	 lysis	 have	
emerged as the most promising options.
The	rationale	beyond	the	use	of	a	reduced-	dose	systemic	fibri-
nolysis regimen has its fundament in cohort studies and in a random-
ized	 pilot	 trial	 of	 118	 patients,	 suggesting	 that	 this	 approach	may	
have	 an	 acceptably	 low	 risk	 of	 (life-	threatening)	 bleeding	without	
loss	of	efficacy	compared	with	standard-	dose	fibrinolysis	(reviewed	
in	Valerio	et	al.80).	To	test	this	hypothesis,	the	PEITHO-	III	randomized	











catheter-	directed	 pharmacological	 regimens	 or	 catheter-	directed	
techniques with standard anticoagulation.81–	84 In most of these 
studies,	an	early	improvement	of	right-	to-	left	ventricular	diameter	
ratio	was	 observed	within	 24-	48	 hours	 of	 PE	 diagnosis.	 Devices	
currently	 approved	 for	 use	 in	 acute	PE	 include	 the	EkoSonic	 en-
dovascular	 system	 for	 ultrasound-	assisted	 catheter-	directed	
thrombolysis	 (Boston	 Scientific,	 Marlborough,	 MA,	 USA)82,83 
and	 the	 large-	bore	 aspiration	 thrombectomy	 FlowTriever	 system	
(Inari	Medical,	Aliso	Viejo,	CA,	USA).84	 Figures	3	 and	4	 illustrate	
two	 exemplary	 patients	with	 acute	 PE	 and	 right	 ventricular	 dys-
function,	 who	 were	 successfully	 treated	 with	 catheter-	directed	
ultrasound-	assisted	 thrombolysis	 at	 the	 University	 Hospital	 of	
Zurich,	Switzerland.	However,	formal	approval	of	medical	devices	
does not obviate the need for rigorous testing and proof of their 
efficacy	and	safety	in	randomized	controlled	trials	with	clinical	out-
comes.	The	recently	announced	HI-	PEITHO	study	is	a	multicenter	
prospective	 randomized	controlled	 trial	 that	will	be	conducted	 in	
the	Unites	States	and	Europe.	It	will	compare	clinical	outcomes	fol-
lowing	ultrasound-	facilitated,	catheter-	directed	thrombolysis	plus	





tional	 outcomes	 and	 complications	 associated	with	 the	 so-	called	
post-	PE	syndrome.85
Five	 small	 randomized	 controlled	 trials	 have	 tested	 the	 use	
of	 catheter-	directed	 reperfusion	 techniques	 in	 patients	 with	
acute	 (proximal)	 DVT	 for	 the	 prevention	 of	 postthrombotic	 syn-
drome.86–	90 The heterogeneity of the study populations and the 
fact that all studies were largely underpowered to detect statisti-
cally	significant	differences	limit	our	ability	to	interpret	their	results,	
leaving	 anticoagulation	 as	 the	 standard	 therapy	 for	 acute	DVT.	A	
post	 hoc	 analysis	 of	 the	 Catheter	 Versus	 Anticoagulation	 Alone	
for	 Acute	 Primary	 (Ilio)Femoral	 DVT	 (CAVA)	 trial	 focused	 on	 the	
effect	 of	 ultrasound-	accelerated	 catheter-	directed	 thrombolysis	
on the development of the postthrombotic syndrome after 1 year 
of	 follow-	up;	 although	 the	 risk	 was	 not	 reduced	 after	 successful	
thrombolysis	for	acute	iliofemoral	DVT,	these	patients	did	report	an	
improvement in the quality of life.91	Finally,	observational	data	sug-
gest that endovascular treatment of postthrombotic syndrome with 
stent	 placement	might	 improve	mid-	 and	 long-	term	 clinical	 (func-
tional)	scores.92,93	The	Aspirin	Plus	Rivaroxaban	Versus	Rivaroxaban	
Alone	 for	 the	Prevention	of	Venous	Stent	Thrombosis	 in	Patients	
With	 Prothrombotic	 Syndrome	 (ARIVA;	 NCT04128956)	 phase	 3	
trial will elucidate which antithrombotic therapy may be most ap-
propriate in this group of patients.
7  |  ANNUAL CONGRESS REPORT
A	number	of	abstracts	highlighting	the	ongoing	translational	research	
on emerging antithrombotic drugs and strategies were presented at 
the	2020	Congress	of	the	International	Society	on	Thrombosis	and	
Haemostasis. Prevention of carotid arterial thrombosis with the oral 
small-	molecule	FXIa	 inhibitor	BMS-	986177	was	 reported	 in	 animal	




bosis	 in	 animal	 models,	 with	 less	 bleeding	 tendency	 compared	 to	
rivaroxaban.95	 Comparison	 of	 the	 intravenous	 small-	molecule	 FXIa	
inhibitor	EP-	7041	with	heparin	for	the	prevention	of	thrombus	for-
mation	 in	 a	 canine	 extracorporeal	 membrane	 oxygenation	 model	
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TA B L E  2 Anticoagulants	currently	at	an	advanced	stage	of	clinical	investigation	in	the	indication	of	VTE,	or	in	particular	patient	groups
Antisense oligonucleotides Antibodies
Name Ionis- 416858 (also BAY- 2306001)50,51,104 Osocimab (BAY- 1213790)52,105 Abelacimab (MAA- 868) Xisomab (AB- 023) BMS- 986177/JNJ- 70033093
Targeted coagulation factor XI XI
Type of substance Second-	generation	antisense	
oligonucleotide











Time	to	peak	effect 4–	6	wk 1–	4	h 0.08–	0.65	h
Half-	life 2	wk 30–	44	d 20.1–	28.6	d 8.26-	13.8	h
Renal elimination Clearance does not depend on renal 
function
Clearance does not depend on renal function 8%-	20%
Interactions with concomitant 
medication
Low	risk	for	drug-	drug	interactions Low	risk	for	drug-	drug	interactions Low	risk	for	drug-	drug	interactions Low	risk	for	drug-	drug	interactions Drug-	drug	interactions	related	to	CYP	
Contraindications or caveats Local	injection	reactions Possible dosing once per month Productive	cough,	probably	not	directly	 Food	may	increase	bioavailability
























TA B L E  3 Published	clinical	trials	on	new	anticoagulants	targeting	factor	XI	in	primary	prevention	of	VTE












































    |  9 of 15MAVROMANOLI et AL.
 Anticoagulants	currently	at	an	advanced	stage	of	clinical	investigation	in	the	indication	of	VTE,	or	in	particular	patient	groups
Small molecules
Name Ionis- 416858 (also BAY- 2306001) Osocimab (BAY- 1213790) Abelacimab (MAA- 868)54 Xisomab (AB- 023)106 BMS- 986177/JNJ- 70033093107
XI XI XI
Second-	generation	antisense	 IgG1 monoclonal antibody IgG2b monoclonal antibody Small-	molecule	inhibitor








Time	to	peak	effect 4–	6	wk 1–	4	h 7– 21 d 0.08–	0.65	h 3 h
Half-	life 2	wk 30–	44	d 20.1–	28.6	d 1.3– 121.5 h 8.26-	13.8	h
Clearance does not depend on renal function Clearance does not depend on renal 
function
8%-	20%
Low	risk	for	drug-	drug	interactions Low	risk	for	drug-	drug	interactions Low	risk	for	drug-	drug	interactions Low	risk	for	drug-	drug	interactions Drug-	drug	interactions	related	to	CYP	
metabolism
Local	injection	reactions Decreased effect in obesity Productive	cough,	probably	not	directly	



















inserted central catheters 
































Ionis 200 mg: 3%
Ionis 300 mg: 3%
compared	to	enoxaparin	40	mg:	8%








































7684	 is	 an	oral	 small-	molecule	FXIa	 inhibitor,	which	was	assessed	
in	a	phase	1	randomized	double-	blind	placebo-	controlled	study	on	
healthy individuals. It demonstrated good tolerability with mild ad-
verse	 effects,	 a	 half-	life	 of	 22-	28	 hours,	 and	 peak	 concentrations	
that	increased	with	food	intake.99	The	safety,	pharmacokinetics,	and	
pharmacodynamics	of	BAY-	2433334	were	also	evaluated	in	a	phase	




In	 the	 past	 decade,	 new	 oral	 drugs	 directly	 targeting	 coagulation	
factor	 Xa	 or	 thrombin	 revolutionized	 the	 treatment	 of	 thrombotic	
diseases	including	VTE.	Nevertheless,	in	a	continuously	growing	pop-
ulation	 of	 possible	 candidates	 for	 long-	term	 anticoagulation,	 safety	




the	 final	 common	 pathway,	 with	 epidemiological	 and	 experimen-
tal	data	pointing	to	FXI	as	a	promising	target.	Of	the	numerous	ap-
proaches	 proposed	 for	 FXI	 inhibition,	 second-	generation	 antisense	
oligonucleotides,	 several	 humanized	 monoclonal	 antibodies,	 and	 a	
F I G U R E  2 Graphical	overview	of	the	main	types	of	available	
reperfusion strategies and techniques for acute pulmonary 
embolism
TA B L E  4 Technologies	for	catheter-	directed	treatment	(adapted	from	Hobohm	et	al.109	and	Valerio	et	al.80)
Technique Description Device (company) Evidence
Catheter-	directed	
thrombolysis
The catheter is inserted directly into the 
pulmonary artery and the thrombolytic 







Observational studies and one 
prospective	randomized	






energy ultrasound transducers which 











The pigtail is inserted into the distal part 


































and are retracted via a vacuum 
aspirator into the catheter.
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number of small molecule inhibitors have completed or are still under-
going	clinical	testing	in	dose-	finding,	phase	2	trials.	The	first	results	
are	promising,	and	each	mode	of	inhibition	may	offer	advantages	for	
specific patient groups and clinical situations. It will soon be possible 
to tell which of these substances will be able to enter phase 3 testing 
as	 the	next	critical	 step	 toward	approval	and	clinical	application.	 In	
parallel,	and	in	view	of	the	recognition	of	the	critical	role	of	FXI	for	
amplifying thrombin generation and thus for hemostasis (indicating a 
remaining	risk	of	bleeding	upon	FXIa	inhibition),	even	safer	targets	are	
being sought among the upstream components of the contact path-
way.	Molecules	of	interest	include	FXII,	polyphosphates,	or	kallikrein,	
although research is still at an earlier phase of translation in this area. 
Finally,	catheter-	directed,	pharmacomechanical	antithrombotic	strat-
egies beyond anticoagulation have been developed for cardiovascular 
emergencies	such	as	high-	and	intermediate-	risk	PE,	and	large	rand-
omized	trials	aiming	to	validate	their	efficacy,	safety,	and	prognostic	
impact are about to start. The revolution that swept antithrombosis in 
the	2010s	will	most	likely	be	followed	by	a	phase	of	targeted	evolution	
in	the	decade	to	come;	although	less	spectacular,	this	phase	will	be	at	
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